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Purpose: This study was designed to investigate the change
of peroxisome proliferator-activated receptor gamma (PPAR ) γ
after the infection of the human coronary artery smooth
muscle cells (HCSMCs) with Chlamydia pneumoniae (C.
pneumoniae) and the effect of PPAR agonist on the expres γ -
sion of PPAR of γ C. pneumoniae-infected HCSMCs. Materials
and Methods: To determine the effect of PPARγ agonist on
the proliferation of C. pneumoniae-infected HCSMCs, rosiglita-
zone at various concentrations was applied 1 hour before
inoculation of HCSMCs. Results: The expression of PPARγ
mRNA in HCSMCs increased from 3 hours after C.
pneumoniae infection and reached that of noninfected
HCSMCs at 24 hours (p < 0.05). The expression of PPARγ
protein in HCSMCs also increased from 3 hours after C.
pneumoniae and persisted until 24 hours as compared with that
of noninfected HCSMCs (p < 0.05). The pretreatment of
HCSMCs with rosiglitazone followed by the infection with C.
pneumoniae augmented the expression of PPAR mRNA and γ
protein (p < 0.05) and decreased cell proliferation. Conclusion:
Our results showed that the expression of PPAR increases in γ
response to C. pneumoniae infection and rosiglitazone further
augmented the expression of PPAR . It is suggested that γ
rosiglitazone could ameliorate the chronic inflammation in the
vessel wall induced by C. pneumoniae by augmenting PPARγ
expression.
Key Words: C. pneumoniae, peroxisome proliferator-activated
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INTRODUCTION
Infection has attracted attention as a novel risk
factor for atherosclerosis, which is different from
traditional risk factors.
1 Among various infectious
agents, Chlamydia pneumoniae (C. pneumoniae) is
the major infectious agent that has been extensively
investigated. Seroepidemiological studies showed
that the seropositivity of anti-C. pneumoniae anti-
bodies is two times higher in patients with cardio-
vascular diseases than that of healthy population
controls.
2 Furthermore C. pneumoniae were
isolated from more than half of atherosclerotic
lesions.
3 In vitro studies suggest that C. pneumoniae
could be detected in circulating leukocytes, and
that they infect all atheroma cell types such as
endothelial cells, vascular smooth muscle cells
(VSMC), and macrophages,
4-6 and induce the
inflammatory cytokines, procoagulants, matrix
metalloproteinases and adhesion molecules.
7-9
Peroxisome proliferator-activated receptor-γ
(PPAR ) is a member of the nuclear receptor γ
superfamily that regulates lipid and lipoprotein
metabolism and glucose homeostasis. In addition,
PPAR has been reported to be an important γ
modulator of the inflammatory response of vessel
wall not only through metabolic effects but also
through their direct action in vascular and
inflammatory cells.
10,11 PPAR is expressed in the γ
major cellular constituents of the vessel wall such
as endothelial cells, VSMC, and macrophages, and
affects development of atherosclerosis.
12,13 In
endothelial cells, PPAR agonist inhibits the γ
expression of monocyte chemoattractant protein-1,
The Effect of Chlamydia pneumoniae on the Expression of
Peroxisome Proliferator-Activated Receptor- in Vascular γ
Smooth Muscle Cells
Yong-Hwan Kim,
1 Si-Young Choi,
1 Jong-Hui Suh,
1 Tae-Kyun Kim,
2 Ki-Bae Seung,
2 Young-Pil Wang,
1
and Kiyuk Chang
2
Departments of
1Cardiothoracic Surgery and
2Internal Medicine, Catholic University College of Medicine, Seoul, Korea.
Received July 31, 2007
Accepted September 27, 2007
The work was supported by Catholic Medical Center Research
Foundation made in the program year of 2005.
Reprint address: requests to Dr. Kiyuk Chang, Department of
Internal Medicine, Catholic University College of Medicine, 65-1
Kumoh-dong, Uijongbu-si, Kyunggi-do 480-130, Korea. Tel: 82-31-
820-3625, Fax: 82-31-847-0461, E-mail: kiyuk@catholic.ac.krThe Effect of Chlamydia pneumoniae and PPARγ
Yonsei Med J Vol. 49, No. 2, 2008
vascular cell adhesion molecule-1, and inter-
cellular adhesion molecule-1.
14,15 PPAR also γ
interferes with leukocyte chemoattraction and
recruitment to atherosclerotic lesions and sup-
presses the expression of inducible nitric oxide
synthase and matrix metalloproteinase-9 (MMP-9)
in macrophages. Furthermore, PPAR inhibits γ
VSMC proliferation by attenuating the mitogen-
induced degradation of p27Kip1, and platelet-
derived growth factor-induced VSMC migration
by inhibiting MMP-9 expression.
11,16
Although a number of studies indicate the role
of PPAR in the modulation of vascular inflam γ -
mation, the effect of atheroprone infectious agents
on the expression of PPAR in vascular cells has γ
not yet been studied. Interestingly, infection
increases PPAR expression in porcine white γ
blood cells
17 but down-regulates it in murine
adipocytes,
18 suggesting that PPAR expression is γ
differentially regulated according to cell types. We
hypothesized that C. pneumoniae infection, which
is a clear risk factor for the development of
atherosclerosis, may have an effect on the
expression of PPAR in vascular smooth muscle γ
cells. Therefore, the present study was undertaken
to investigate whether C. pneumoniae infection
could affect the expression of PPAR in human γ
coronary artery smooth muscle cells (HCSMC).
MATERIALS AND METHODS
Cell lines
Human coronary artery smooth muscle cells
(HCSMC) were purchased from Clonetics and
cultured in SmBm media (smooth muscle cell
basal media, Clonetics, Walkersville, MD, USA).
Passages between 5 and 10 were used.
C. pneumoniae
C. pneumoniae AR-39 strain was purchased from
the American Type Culture Collection (ATCC,
Manassas, VA, USA). The organisms were inocu-
lated into shell vials containing McCoy cells
(ATCC, Manassas, VA, USA), and then shell vials
were centrifuged at 1500g for 1 hour and incu-
bated in RPMI 1640 medium containing 1 g/mL μ
cycloheximide (Sigma, St. Louis, MO, USA). After
48 hours, the infected cells were disrupted by
ultrasonication, and culture supernatants and cell
debris were removed by centrifugation at 800g for
10 minutes. The organisms were then concen-
trated by a high-speed centrifugation at 30,000g
for 30 minutes. The bacterial pellets were resus-
pended in sucrose phosphate glutamate transport
medium and stored at -70 until use. The organisms
resuspended in RPMI 1640 medium were used for
experiments. The number of infectious C. pneumoniae
was determined as inclusion forming units per
mL by counting chlamydial inclusions formed in
McCoy cells with fluorescein isothiocyanate-
conjugated C. pneumoniae-specific monoclonal
antibody (DAKO, Copenhagen, Denmark).
Infection of HCSMC with C. pneumoniae
HCSMCs were trypsinized and plated at a
density of 4 × 10
5 cells/well on 6-well plates. Once
confluent, the medium was then changed to
serum-free medium for 24 hour to achieve
synchronous growth arrest. HCSMCs were
inoculated with C. pneumoniae at a multiplicity of
infection (MOI) of 2, and the plates were centri-
fuged at 500g for 1 hour at room temperature.
Multiple inclusion bodies in HCSMCs were
observed after 48 hours of C. pneumoniae infection.
Cell proliferation assay
HCSMCs were plated at a density of 5 × 10
3
cells/well on 96-well plates and inoculated with
C. pneumoniae by the method described above.
Cell proliferation was determined using XTT pro-
liferation assay kit (JBI, Deagu, Korea) 6 hours, 24
hours and 48 hours after inoculation. As a control
for cell proliferation, noninfected HCSMCs were
used. To determine the effect of a PPAR agonist γ
on the proliferation of C. pneumoniae-infected
HCSMCs, rosiglitazone (GlaxoSmithKline Cor-
porate, King of Prussia, PA, USA) at various con-
centrations was applied 1 hour before inoculation.
Real time reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA was extracted from HCSMCs usingYong-Hwan Kim, et al.
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TRIZOL Reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. Total
extracted RNA was subjected to reverse transcrip-
tion using an onestep RT kit (Invitrogen). Expres-
sions of PPAR and glyceraldehyde 3-phosphate γ
dehydrogenase (GAPDH) were examined in real
time PCR using an SYBR Green dye. Primers used
were as follows: human PPAR sense, 5’-TCTCTC γ
CGTAATGGAAGACC-3’, human PPAR anti γ -
sense, 5’-CCCCTACAGAGTATTACG-3’; GAPDH
sense, 5’-TGCACCACCAACTGCTTAGC-3’, GAPDH
antisense 5’-GGCATGGACTGTGGTCAT GAG-3’.
To examine the changes in the expression of
PPAR mRNA according to time elapse after γ C.
pneumoniae infection in HCSMCs, relative values
were compared at various time intervals.
Western blot analysis
HCSMCs were seeded at 4 × 10
5 cells/well in
6-well plates and incubated with C. pneumoniae.
After various time intervals, cells were harvested,
lysed, and sonicated in Tris-lysate buffer [20 mM
Tris-HCl (pH 7.4), 5 mM EDTA, 10 mM Na2P2O7,
100 mM NaF, 2 mM Na3VO4, 1 mM phenylme-
thylsulfonyl fluoride, 10 g/mL aprotinin, 10 μ g/ μ
mL leupeptin]. Cell lysate were cleared by
centrifugation, and protein concentrations were
determined by Bradford protein assay kit (Pierce,
Rockford, IL, USA). Proteins were resolved on a
9% sodium dodecylsulfate-polyacrylamide gel,
and electrophorectically transferred onto a nitro-
cellulose membrane. The membrane was incubated
with anti-PPAR monoclonal antibody (Santa γ
Cruz Biotechnology, Santa Cruz, CA, USA). HRP-
conjugated anti-mouse IgG (Amersham Bioscience,
Piscataway, NJ, USA) was used as a secondary
antibody. The antigen-antibody complexes were
detected using enhanced chemilumnescence kit
(Amersham Bioscience). Quantification of the
protein band was done by densitometry.
Statistics
Statistical analysis was performed using the
Statistical Package for Social Sciences (version 10,
SPSS Inc., Chicago, IL, USA). Values of continuous
variables are expressed as mean ± standard
deviation. Comparisons of data were made using
Student t-test. P-values less than 0.05 were con-
sidered as indicative of statistical significance.
RESULTS
C. pneumoniae stimulates HCSMCs proliferation
HCSMC proliferation was compared between C.
pneumoniae-infected and uninfected-HCSMCs,
according to time intervals such as 6, 24, and 48
hours after infection at a MOI of 2. As shown in
Fig. 1, HCSMCs proliferation was stimulated after
inoculation with C. pneumoniae in a time-depen-
dent manner. At 48 hours, XTT assay showed that
C. pneumoniae significantly increased the number
of HCSMCs compared to the uninfected control
(Fig. 1).
Rosiglitazone suppresses C. pneumoniae-induced
proliferation of HCSMCs.
To explore whether PPAR activation directly γ
affects C. pneumoniae-induced HCSMCs prolifera-
tion, the proliferation rate was compared between
C. pneumoniae-infected HCSMCs and rosiglitazone-
treated C. pneumoniae-infected HCSMCs. Treat-
ment of HCSMCs with 10 and 50 M rosiglitazone μ
significantly decreased the C. pneumoniae-induced
proliferation of HCSMCs from 5 hours after C.
Fig. 1. Cell proliferation assay of HCSMCs infected with
Chlamydia pneumoniae. Cell proliferation was assessed
by XTT proliferation assay kit (JBI, Daegu, Korea). Changes
in cell proliferation are expressed by a percentage of the
mean value of control (uninfected HCSMCs). *p < 0.05.The Effect of Chlamydia pneumoniae and PPARγ
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pneumoniae infection and from 8 hours even at 1
M concentration (Fig. 2). μ
C. pneumoniae upregulates the expression of
PPAR mRNA expression in HCSMCs γ
To determine whether C. pneumoniae activates
PPAR mRNA in HCSMCs, cells were left γ
untreated or stimulated with C. pneumoniae, and
cDNA was then prepared from each HCSMCs
after 3-, 6-, and 24-hour exposure to C. pneumoniae.
The expression of PPAR mRNA was evaluated γ
by real time RT-PCR. The levels of PPAR mRNA γ
were significantly increased in HCSMCs 3 hours
after C. pneumoniae inoculation, and remained
elevated until 6 hours after infection as compared
with uninfected control. At 24 hours, the level of
PPAR mRNA in HCSMCs infected with γ C.
pneumoniae returned to the level of uninfected
control (Fig. 3).
C. pneumoniae stimulates the expression of PPARγ
protein in HCSMCs
To investigate whether C. pneumoniae infection
affects PPAR protein expression in HCSMCs, γ
cells were stimulated with C. pneumoniae infection
for 3, 6, and 24 hours. Cell lysates were analyzed
by Western blot using a anti-PPAR monoclonal γ
antibody. The levels of PPAR protein were γ
already increased in HCSMCs after 3-hour ex-
posure to C. pneumoniae as compared with
uninfected HCSMCs, and the status of elevation
was maintained until 24 hours (Fig. 4).
Fig. 2. Dose-dependent effects of rosiglitazone on the pro-
liferation of HCSMCs infected with Chlamydia pneumoniae
during 24 hours. *p < 0.05.
Fig. 3. Real time RT-PCR of PPAR in HCSMCs infected γ
with Chlamydia pneumoniae. Relative value was arbitarily
defined as corrected for GAPDH mRNA value. CP
represents Chlamydia pneumoniae. *p < 0.05 vs CP(-).
Fig. 4. Western blot analysis of PPAR in HCSMCs γ
infected with Chlamycia pneumoniae. After 3, 6, and 24
hours, cells were subjected to 10% SDS-PAGE and blotted
with anti-PPAR monoclonal antibody. Expression levels γ
of PPAR were quantified by densitometry. * γ p < 0.05 vs
CP (-).Yong-Hwan Kim, et al.
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PPAR activator further increases the expression γ
of PPAR protein in γ C. pneumoniae-infected
HCSMCs
The observation that C. pneumoniae has a stimu-
latory effect on PPAR protein in HCSMCs pro γ -
mpted us to investigate the potential synergistic
effect of rosiglitazone on the expression of PPARγ
in HCSMCs. Thus, HCSMC cells were divided
into untreated control, C. pneumoniae-inoculated,
rosiglitazone (20 M)-treated, and co-treated with μ
both rosiglitazone and C. pneumoniae. Changes in
the expression of PPAR in each HCSMCs were γ
evaluated by Western blot 24 hours after treatment.
As compared with untreated control, both rosig-
litazone and C. pneumoniae significantly increased
the expression of PPAR protein in HCSMCs. γ
Interestingly, co-treatment of HCSMCs with rosig-
litazone and C. pneumoniae resulted in an additive
effect on the expression of PPAR protein (Fig. 5). γ
DISCUSSION
The present study shows that C. pneumoniae
could upregulate the expression of PPAR mRNA γ
and protein in HCSMCs, and PPAR activator γ
further increased its expression in concert with C.
pneumoniae. In addition, rosiglitazone significantly
attenuated C. pneumoniae-induced proliferation of
HCSMCs. Our results suggest that PPAR palys γ
a role in the development of atherosclerosis
induced by C. pneumoniae. It is suggested that
rosiglitazone, a PPAR agonist, could prevent the γ
development of atherosclerosis through its anti-
inflammatory and anti-atherogenic effects.
C. pneumoniae could infect and proliferate
within endothelial cells, vascular smooth muscle
cells, and macrophages, and evoke inflammatory
response in these cells.
4-9 Animal model studies
have shown that C. pneumoniae could infect vessel
wall and cause arterial inflammation, which leads
to the initiation and development of athero-
sclerotic lesions.
19,20 In contrast, PPAR has an γ
important effect of inhibiting growth and migra-
tion of all vascular cells, and reducing vessel in-
flammation, which leads to attenuation of athero-
sclerosis in the vessel wall.
12,13,16,21-23 However, the
influence of C. pneumoniae infection on the PPARγ
in atherosclerosis-related vascular cells has not yet
been studied. Since PPAR is expressed in all γ
vascular cells and has significant effects on the
protection from vessel inflammation, it is of value
to demonstrate the effect of C. pneumoniae on the
PPAR in vascular cells. γ
Few studies have evaluated the association
between infection and PPAR . Leininger et al. γ
reported that in vivo lipopolysaccharide challenge
caused a dynamic increase in PPAR protein γ
expression in peripheral white blood cells.
17 In
tissues of Helicobacter pylori-induced atrophic
gastritis or gastric carcinoma, the expression of
PPAR was upregulated, γ
24 and Huang B et al.
showed that the expression of PPAR was γ
upregulated in the endothelial cells in mice
infected with C. pneumoniae.
25 In the present study,
we also observed that C. pneumoniae stimulated
the expression of PPAR in vascular smooth γ
muscle cells. This observation was contrary to the
expectation that C. pneumoniae might suppress the
expression of PPAR because of their counter γ -
balancing actions on all the vascular cells and
vessel walls. However, the mechanisms of C.
pneumoniae-induced PPAR activation in HCSMCs γ
are not clear. C. pneumoniae is a Gram-negative
Fig. 5. Western blot analysis of PPAR in HCSMCs infected γ
with Chlamydia pneumoniae and/or treated with rosi-
glitazone (20 M). After 24 hours, cells were subjected to μ
10% SDS-PAGE and blotted with anti-PPAR mono γ clonal
antibody. Expression levels of PPAR were quantified by γ
densitometry. *p < 0.05 vs CP(-).The Effect of Chlamydia pneumoniae and PPARγ
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bacterium, and its cell wall is rich in lipopoly-
saccharides, which can induce hepatocytes and
macrophages to secret prostaglandin (PG) D2.
26,27
15d-PGJ2, a metabolite of PGD2, is a ligand for
PPAR and can induce the PPAR expression. γ γ
Further study is needed to elucidate in detail the
mechanism of C. pneumoniae-induced PPARγ
upregulation in vitro.
The increase of PPAR expression may act as an γ
counter-regulatory mechanism of attenuating the
negative effect of C. pneumoniae in HCSMCs.
Rosiglitazone suppressed C. pneumoniae-induced
proliferation of HCSMCs and further elevated the
expression of PPAR protein. It might be a novel γ
mechanism of PPAR activators to be protective γ
against the atheroprone C. pneumoniae. Further
studies are required to clarify the association and
influence between infection and PPAR in γ
vascular cells as well as in animal models.
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